Page 55 - Read Online

Page 14 Biersack. Cancer Drug Resist 2019;2:1-17 I http://dx.doi.org/10.20517/cdr.2019.09

19. Singh RK, Kumar S, Prasad DN, Bhardwai TR. Therapeutic journey of nitrogen mustards alkylating anticancer agents: historic to future
perspectives. Eur J Med Chem 2018;151:401-33.
20. Goede V, Eichhorst B, Fischer K, Wendtner CM, Hallek M. Past, present and future role of chlorambucil in the treatment of chronic
lymphocytic leukemia. Leuk Lymphoma 2015;56:1585-92.
21. Zenz T, Mohr J, Edelmann J, Sarno A, Hoth P, et al. Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway.
Leuk Lymphoma 2009;50:510-3.
22. Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, et al. MiR-34a as part of the resistance network in chronic lymphocytic leukemia.
Blood 2009;113:3801-8.
23. Battistella M, Romero M, Castro-Vega LJ, Gapihan G, Bouhidel F, et al. The high expression of the microRNA 17-92 cluster and its
paralogs, and the downregulation of the target gene PTEN, is associated with primary cutaneous B-cell lymphoma progression. J Invest
Dermatol 2015;135:1659-67.
24. Costales MG, Haga CL, Velagapudi SP, Childs-Disney JL, Phinney DG, et al. Small molecule inhibition of microRNA-210 reprograms
an oncogenic hypoxic circuit. J Am Chem Soc 2017;139:3446-55.
25. Zweegman S, Huijgens PC. Treatment of myeloma: recent developments. Anticancer Drugs 2002;13:339-51.
26. Manier S, Liu CJ, Avet-Loiseau H, Park J, Shi J, et al. Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood
2017;129:2429-36.
27. Hao M, Zhang L, An G, Sui W, Yu Z, et al. Suppressing miRNA-15a/16 expression by interleukin-6 enhances drug-resistance in
myeloma cells. J Hematol Oncol 2011;4:37.
28. Zhao JJ, Chu ZB, Hu Y, Lin J, Wang J, et al. Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone
resistance in multiple myeloma. Cancer Res 2015;75:4384-97.
29. Gullá A, Di Martino MT, Cantafio MEG, Morelli E, Amodio N, et al. A 13 mer LNA-i-miR-221 inhibitor restores drug sensitivity in
melphalan-refractory multiple myeloma cells. Clin Cancer Res 2015;22:1222-33.
30. Du J, Liu S, He J, Liu X, Qu Y, et al. MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling
pathway in multiple myeloma. Oncotarget 2015;6:14993-5007.
31. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009;6:638-47.
32. Boddy AV, Yule SM. Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 2000;39:291-304.
33. Zhang J, Tian Q, Chan SY, Duan W, Zhou S. Insights into oxaphosphorine resistance and possible approaches to its circumvention.
Drug Resist Updat 2005;8:271-97.
34. Cho WCS. Great potential of microRNAs as predictive and prognostic markers for cancer. Expert Rev Mol Diagn 2012;12:315-8.
35. Yu X, Li Z. New insights into microRNAs involves in drug resistance in diffuse large B cell lymphoma. Am J Transl Res 2015;7:2536-42.
36. Yuan WX, Gui YX, Na WN, Chao J, Yang X. Circulating microRNA-125b and microRNA-130a expression profiles predict
chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett 2016;11:423-32.
37. Alencar AJ, Malumbres R, Kozloski GA, Advani R, Talreja N, et al. MicroRNAs are independent predictors of outcome in diffuse large
B-cell lymphoma patients treated with R-CHOP. Clin Cancer Res 2011;17:4125-35.
38. Montes-Moreno S, Martinez N, Sanchez-Espiridión B, Uriarte RD, Rodriguez ME, et al. MiRNA expression in diffuse large B-cell
lymphoma treated with chemoimmunotherapy. Blood 2011;118:1034-40.
39. Bai H, Wei J, Deng C, Yang X, Wang C, et al. MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the
CHOP chemotherapy regimen. Int J Hematol 2013;97:223-31.
40. Zheng Z, Li X, Zhu Y, Gu W, Xie X, et al. Prognostic significance of miRNA in patients with diffuse large B-cell lymphoma: a meta-
analysis. Cell Physiol Biochem 2016;39:1891-904.
41. Berglund M, Hedstrom G, Amini RM, Enblad G, Thunberg U. High expression of microRNA-200c predicts poor clinical outcome in
diffuse large B-cell lymphoma. Oncol Rep 2013;29:720-4.
42. Iqbal J, Shen Y, Huang X, Liu Y, Wake L, et al. Global microRNA expression profiling uncovers molecular markers for classification
and prognosis in aggressive B-cell lymphoma. Blood 2015;125:1137-45.
43. Hedstrom G, Thunberg U, Berglund M, Simonsson M, Amini RM, et al. Low expression of microRNA-129-5p predicts poor clinical
outcome in diffuse large B cell lymphoma (DLBCL). Int J Hematol 2013;97:465-71.
44. Huang H, Gu J, Yao S, Yao Z, Zhao Y, et al. MicroRNAs are related to rituximab with cyclophosphamide, doxorubicin, vincristine, and
prednisone resistance in patients with diffuse large B-cell lymphoma. Cancer Transl Med 2015;1:6-10.
45. Wu PY, Zhang XD, Zhu J, Guo XY, Wang JF. Low expression of microRNA-146b-5p and microRNA-320d predicts poor outcome of
large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone. Hum Pathol 2014;45:1664-73.
46. Song G, Gu L, Li J, Tang Z, Liu H, et al. Serum microRNA expression profiling predict response to R-CHOP treatment in diffuse large
B cell lymphoma patients. Ann Hematol 2014;93:1735-43.
47. Chigrinova E, Mian M, Shen Y, Greiner TC, Chan WC, et al. Integrated profiling of diffuse large B-cell lymphoma with 7q gain. Br J
Haematol 2011;153:499-503.
48. Salter KH, Acharya CR, Walters KS, Redman R, Anguiano A, et al. An integrated approach t the prediction of chemotherapeutic
response in patients with breast cancer. PLoS One 2008;3:e1908.
49. Sun G, Sun L, Liu Y, Xing H, Wang K. Her-2 expression regulated by downregulation of miR-9 and which affects chemotherapeutic
effect in breast cancer. Cancer Gene Ther 2017;24:194-202.
50. Gezer U, Keskin S, Igci A, Tükenmez M, Tiryakioglu D, et al. Abundant circulating microRNAs in breast cancer patients fluctuate
considerably during neoadjuvant chemotherapy. Oncol Lett 2014;8:845-8.